Literature DB >> 16507856

Percutaneous computed tomography-guided radiofrequency thermal ablation of small unresectable lung tumours.

S Rossi1, R Dore, A Cascina, V Vespro, F Garbagnati, L Rosa, V Ravetta, A Azzaretti, P Di Tolla, G Orlandoni, E Pozzi.   

Abstract

The aim of the current study was to evaluate the safety and the efficacy of radiofrequency thermal ablation (RFTA) for the treatment of nonsmall cell lung cancer (NSCLC) and isolated pulmonary metastases (METs) from colorectal cancer (CRC). A total of 31 patients (15 with NSCLCs and 16 with CRC lung METs), with 36 lung tumour nodules (mean+/-sd diameter: 22+/-8 mm, range: 10-35 mm) underwent computed tomography (CT)-guided RFTA using expandable electrodes. Contrast-enhanced CT was performed before and after (immediately and 30+/-5 days) each RFTA session to assess immediate results and complications and repeated 3 and 6 months post-RFTA, as well as every 6 months thereafter, to evaluate long-term results. Complete radiological necrosis was defined as a nonenhancing area at the tumour site that was equal to or larger than the treated tumour; persistence of enhancement at the tumour site indicated incomplete treatment. Local recurrence was defined as an increase in tumour size and/or enhancing tissue at the tumour site. Complete radiological necrosis of the 36 tumours was achieved with 39 RFTA sessions and 42 electrode insertions. No major complications or deaths were observed. Six patients experienced mild-to-moderate pain during the procedure. There were five cases of pneumothorax, none requiring drainage and four cases of pneumonia, which were successfully treated with antibiotics. After a mean follow-up of 11.4+/-7.7 months (range of 3-36 months), the overall local recurrence rate was 13.9% (20 and 9.5% for NSCLC and CRC-METs patients, respectively). Nineteen of the 31 (61.3%) patients were alive (15 apparently disease free) and 12 (38.7%) had died (three from causes unrelated to their cancer). Radiofrequency thermal ablation seems to be a safe, effective method for producing complete ablation of small nonsmall cell lung cancers and pulmonary colorectal cancer metastases.

Entities:  

Mesh:

Year:  2006        PMID: 16507856     DOI: 10.1183/09031936.06.00052905

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  7 in total

Review 1.  Lung radiofrequency and microwave ablation: a review of indications, techniques and post-procedural imaging appearances.

Authors:  S L Smith; P E Jennings
Journal:  Br J Radiol       Date:  2014-12-03       Impact factor: 3.039

Review 2.  Thermal ablation of malignant lung tumors.

Authors:  Thomas Schneider; Claus Peter Heussel; Felix J F Herth; Hendrik Dienemann
Journal:  Dtsch Arztebl Int       Date:  2013-05-31       Impact factor: 5.594

3.  Radiofrequency ablation of metastatic lesions from breast cancer.

Authors:  C Bortolotto; S Macchi; L Veronese; R Dore; F Draghi; S Rossi
Journal:  J Ultrasound       Date:  2012-06-27

Review 4.  RFA of primary and metastatic lung tumors: long-term results.

Authors:  Stefano Giusto Picchi; Giulia Lassandro; Andrea Bianco; Andrea Coppola; Anna Maria Ierardi; Umberto G Rossi; Francesco Lassandro
Journal:  Med Oncol       Date:  2020-03-27       Impact factor: 3.064

5.  Radiofrequency ablation of lung tumours.

Authors:  Pyt Goh
Journal:  Biomed Imaging Interv J       Date:  2006-07-01

6.  The challenge of extraabdominal desmoid tumour management in patients with Gardner's syndrome: radiofrequency ablation, a promising option.

Authors:  Lorenzo Cobianchi; Valentina Ravetta; Francesca Torello Viera; Claudia Filisetti; Barbara Siri; Edoardo Segalini; Marcello Maestri; Tommaso Dominioni; Mario Alessiani; Sandro Rossi; Paolo Dionigi
Journal:  World J Surg Oncol       Date:  2014-11-27       Impact factor: 2.754

7.  Efficacy of radiofrequency ablation and microwave ablation in the treatment of thoracic cancer: A systematic review and meta-analysis.

Authors:  Yuan-Dong Sun; Hao Zhang; Jing-Zhou Liu; Hui-Rong Xu; Hui-Yong Wu; Hui-Zhuan Zhai; Chang-Yan Lu; Xia Zhao; Ye-Qiang Chen; Lin-Lin Zhou; Jian-Jun Han
Journal:  Thorac Cancer       Date:  2019-01-24       Impact factor: 3.500

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.